Head-to-head · Value Score
CoreAge Rx vs NuuVim
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, NuuVim a 77. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$149/mo
Save ~89% vs brand-nameNuuVim
#108 · Grade B- · Fair Price
Est. first month
From $79/mo (all doses, compounded)
Save ~94% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 77 — an est. $149/mo first month, with no teaser step-up baked in. NuuVim isn't out of it: Shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | NuuVim |
|---|---|---|
| Value Score | 93 (A+) | 77 (B-) |
| Est. first month | $149/mo | From $79/mo (all doses, compounded) |
| Save vs brand-name | ~89% | ~94% |
| Semaglutide | $149/mo | From $79/mo (all doses, compounded) |
| Tirzepatide | $349/mo | From $133/mo (all doses, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
NuuVim
NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
Why it's a deal
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
The fine print
- No founder, CEO, medical director, or pharmacist-in-charge named
- Refund and cancellation policy not surfaced on the site
- Compounded medications are not FDA-approved
- Doesn't disclose which pharmacy fills which drug or form
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to NuuVim.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.